British Biotech: how much value is there in metalloproteinase inhibitors?

Author： Thomas S.M. Falkenherr R. Burke J.F.

ISSN： 1354-3776

Source： Expert Opinion on Therapeutic Patents, Vol.7, Iss.7, 1997-07, pp. : 687-693

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

How Much Is Too Much?

By COLEMAN WILLIAM P.

Dermatologic Surgery, Vol. 22, Iss. 11, 1996-11 ,pp. : 978-978

Elsevier

Access to resources Recommend Favorite

Matrix metalloproteinase inhibitors

Expert Opinion on Therapeutic Patents, Vol. 7, Iss. 10, 1997-10 ,pp. : 1213-1216

Informa Healthcare

Access to resources Recommend Favorite

Matrix metalloproteinase inhibitors and cancer

By Lauer-Fields J.L. Fields G.B.

Expert Opinion on Therapeutic Patents, Vol. 10, Iss. 12, 2000-12 ,pp. : 1873-1884

Informa Healthcare

Access to resources Recommend Favorite

Matrix metalloproteinase inhibitors 1998

By Beckett R.P. Whittaker M.

Expert Opinion on Therapeutic Patents, Vol. 8, Iss. 3, 1998-03 ,pp. : 259-282

Informa Healthcare

Access to resources Recommend Favorite

The Case of Biotech-Derived Product Equivalence: Much Ado About Nothing?

Current Clinical Pharmacology, Vol. 1, Iss. 2, 2006-05 ,pp. : 147-156

Bentham Science Publishers

Access to resources Recommend Favorite